Glioblastoma Multiforme (GBM) is the most frequently occurring type of primary tumors of the central nervous system (CNS) mostly in adults, and its poor prognosis has not been significantly improved even though the innovative diagnostic strategies and new therapies have been developed.
&nbsp;
Glioblastoma Multiforme Epidemiological Segmentation&nbsp;
The Epidemiological Segmentation of Glioblastoma Multiforme in 7MM from 2017 to 2030 is segmented as:-&nbsp;
<ul>
<li>Total Diagnosed Incident Population</li>
<li>Gender-specific Diagnosed Incidence</li>
<li>Type-specific Diagnosed Incidence</li>
<li>Age-specific Diagnosed Incidence</li>
<li>Diagnosed Incident Population-based on Primary Site</li>
<li>Diagnosed Incident Population-based on Histologic Classification</li>
</ul>
&nbsp;
<a style="color: #0047b2; background-color: transparent;" href="https://www.delveinsight.com/report-store/glioblastoma-multiforme-gbm-epidemiology-forecast" target="_blank" rel="noopener noreferrer">Glioblastoma Multiforme Epidemiology</a>&nbsp;
<ul>
<li>The total diagnosed incident population of GBM in 7MM in 2017 was 28,259&nbsp;&nbsp;</li>
<li>The diagnosed incident cases of GBM in the United States in 2017 was 14,666</li>
</ul>
&nbsp;
<a style="background-color: transparent; color: #0047b2;" href="https://www.delveinsight.com/report-store/glioblastoma-multiforme-gbm-market" target="_blank" rel="noopener noreferrer">Glioblastoma Multiforme Market</a>
The market size of GBM in 7MM in 2017 was USD 1,005 Million&nbsp;&nbsp;
&nbsp;
Glioblastoma Multiforme Market Drivers
<ul>
<li>Robust Pipeline Activity</li>
<li>Upcoming Launches and Approval</li>
<li>Improved Treatment Deliverance</li>
<li>Emergence of Immunotherapies</li>
<li>Advancements in Genomics and Proteomics</li>
<li>Low Cost of Treatment</li>
<li>Interventions that can Cross the Blood-Brain-Barrier</li>
</ul>
&nbsp;
Glioblastoma Multiforme Market Barriers
<ul>
<li>Use of Off Label Therapies and Generics</li>
<li>High Treatment Cost</li>
<li>Fewer Patients Available for Clinical Trials</li>
<li>High Recurrence Rate</li>
<li>Multiple Treatment Challenges</li>
</ul>
&nbsp;
<a style="color: #0047b2; background-color: transparent;" href="https://www.delveinsight.com/report-store/glioblastoma-multiforme-gbm-pipeline-insight" target="_blank" rel="noopener noreferrer">Glioblastoma Multiforme Emerging Drugs</a>
The emerging drugs of the Glioblastoma Multiforme market are&nbsp;
<ul>
<li>Ofranergene obadenovec (VB-111)&nbsp;&nbsp;</li>
<li>Trans Sodium Crocetinate&nbsp;&nbsp;</li>
<li>Regorafenib&nbsp;</li>
<li>Durvalumab (MEDI4736)&nbsp;&nbsp;</li>
<li>Tasadenoturev (DNX-2401)&nbsp;&nbsp;</li>
<li>ONC201&nbsp;&nbsp;</li>
<li>Selinexor (KPT-330)&nbsp;&nbsp;</li>
<li>VBI-1901&nbsp;&nbsp;</li>
<li>Paxalisib (GDC-0084)&nbsp;&nbsp;</li>
<li>AV-GBM-1&nbsp;&nbsp;</li>
<li>MDNA55&nbsp;&nbsp;</li>
<li>VAL-083 (Dianhydrogalactitol)&nbsp;&nbsp;</li>
<li>ITI-1000 (pp65 DC Vaccine)&nbsp;&nbsp;</li>
<li>INO-5401+ INO-9012+ Cemiplimab (REGN2810)&nbsp;&nbsp;</li>
</ul>
And many others.
&nbsp;
Glioblastoma Multiforme Key Players
The key players in the Glioblastoma Multiforme market are
<ul>
<li>VBL Therapeutics</li>
<li>Diffusion Pharmaceuticals</li>
<li>Bayer</li>
<li>MedImmune</li>
<li>DNAtrix</li>
<li>Oncoceutics</li>
<li>Karyopharm Therapeutics</li>
<li>VBI Vaccines</li>
<li>Kazia Therapeutics</li>
<li>Aivita Biomedical</li>
<li>Medicenna Therapeutics</li>
<li>Kintara Therapeutics</li>
<li>Immunomic Therapeutics</li>
<li>Inovio Pharmaceuticals</li>
</ul>
And many others.
&nbsp;
Stay tuned for recent updates on <a style="background-color: transparent; color: #0047b2;" href="https://www.delveinsight.com/blog/gbm-market" target="_blank" rel="noopener noreferrer">Glioblastoma Multiforme Treatment Market</a>

Glioblastoma Multiforme Market

Glioblastoma Multiforme Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.